全部 标题 作者 关键词 摘要
DOI: 10.3971/j.issn.1000-8578.2016.09.009
Keywords: Partial Versus Radical Nephrectomy,Apatinib Treatment for Primary Liver Cancer with Lung Metastasis: A Case Report,Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Metaanalysis,Advance of Immune Checkpoint Inhibitors in Therapy of Liver Cancer,Relationship of Macrophage Migration Inhibitory Factor Expression with Clinicopathologic Features and Prognosis of Cardiac Carcinoma Patients,Advance of Prognostic Markers of Cervical Cancer,Metaplastic Carcinoma of Breast with Mesenchymal Differentiation: 28 Cases Report
Full-Text Cite this paper Add to My Lib
摘要 目的 探讨原发性肝癌(HCC)患者肝癌组织中CD68+肿瘤相关巨噬细胞(CD68+ TAM)的数量与增殖指标Ki-67及肝癌预后的关系,寻找评估肝癌预后更可靠的指标。方法 应用免疫组织化学SABC法检测73例HCC组织中CD68+ TAM的分布情况及增殖指标Ki-67蛋白表达,运用化学发光测定法检测血清AFP水平。结果 CD68+ TAM高密度组Ki-67阳性率明显高于低密度组(P=0.0191)。CD68+ TAM数量与HCC患者的年龄、性别无关(P>0.05),而与HCC病理分级有关(P=2.83E-04)。血清AFP水平与HCC患者的年龄、性别、病理分级无关(P>0.05)。CD68+ TAM高密度组的总生存时间显著短于低密度组(P=0.0004)。而AFP高水平组与低水平组比较,总生存时间、Ki-67阳性率差异均无统计学意义(P>0.05)。结论 HCC患者肝癌组织中CD68+ TAM数量与肝癌增殖活性密切相关,是HCC预后的独立危险因素。与AFP相比,CD68+ TAM有望成为评估肝癌预后更可靠的指标
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133